SOPHiA GENETICS appoints Kathy L. Hibbs to Board of Directors

Health tech company SOPHiA GENETICS has announced the appointment of Kathy L. Hibbs to its Board of Directors and Audit Committee. Ms. Hibbs is Chief Legal and Regulatory Officer at consumer genetics and research company 23andMe, and will bring her expertise as an accomplished healthcare technology executive to help guide SOPHiA’s leaders.

"We are pleased to welcome Kathy to SOPHiA's Board of Directors," said SOPHiA GENETICS' CEO and Founder Jurgi Camblong. "The company will significantly benefit from Kathy's extensive experience in legal and regulatory affairs in the biotech industry specifically. She substantially contributed to the accessibility of genetic testing and usage of real-world evidence data, leading millions of people to more proactive health decisions, and is therefore totally aligned with our mission to democratize Data-Driven Medicine."

Ms. Hibbs is considered one of the most influential women in the Bay Area by both the San Francisco and Silicon Valley Business Journals, and one of the most influential General Counsels in the U.S. by Chambers. She has 15 years of experience as an executive officer and corporate secretary for biotechnology companies Genomic Health, Inc. and Monogram Biosciences, Inc..

"SOPHiA's position in the market and its rapid penetration in the US make it an exciting time to join the company," said Ms. Hibbs. "We share a common passion and a commitment to bring personalized medicine to the next chapter of its development; I find it truly inspiring, and I look forward to bringing my experience to the board."

More announcements from SOPHiA GENETICS

Team announcement

SOPHiA GENETICS adds Bram Goorden to executive team

Health tech company SOPHiA GENETICS has welcomed Bram Goorden to its Executive team as Chief Commercial Officer and Head of North America. In his role, Mr. Goorden will be based in Boston, and help to facilitate the company’s goals to triple its US-based team. "Bram is an amazing addition to our leadership team as he is well-versed in building top performing teams and developing lasting commercial relationships with healthcare stakeholders that are of immense benefit to all involved,” said SOPHiA GENETICS founder and CEO Jurgi Camblong. “He will be a great driver of our US and Global expansion plans moving forward as he champions the future of Data-Driven Medicine in both the Clinical and BioPharma Business Units." Mr. Goorden is a Belgian national with more than 20 years of experience in the life science field. He comes to SOPHiA from Foundation Medicine Inc., where he served as VP of International Business and Partnering. He has also served in leadership positions at Prometheus Labs, Eli Lilly and UCB Pharma. "I am thrilled to join the SOPHiA team. Our universal Platform is democratizing Data-Driven Medicine in an unparalleled fashion,” said Mr. Goorden. “Together, we enable healthcare providers to fully utilize the power of decentralized genomic and multimodal data in their efforts to improve patient outcomes. It's a privilege to help grow access to our solution for both clinicians and biopharma partners in my role as Chief Commercial Officer."

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.